On Thursday, GlaxoSmithKline plc (ADR) (NYSE:GSK)’s shares declined -0.10% to $38.79.
GlaxoSmithKline and Theravance, Inc. declared initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for Relvar®/Breo® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’). The study involved 16,485 patients from 43 countries who had chronic obstructive pulmonary disease (COPD) with moderate airflow limitation (FEV1 50-70% predicted) and either a history or raised risk of cardiovascular disease (CVD).
For the primary endpoint of the study, the risk of dying on FF/VI 100/25mcg was 12.2% lower than on placebo* over the study period, which was not statistically noteworthy(p=0.137).
For the first of two secondary endpoints, FF/VI 100/25mcg reduced the rate of lung function decline (as measured by forced expiratory volume in one second, ‘FEV1’) by 8mL per year contrast with placebo (p=0.019). As the primary endpoint was not met, statistical significance cannot be inferred from this result. For the other secondary endpoint, the risk of experiencing an on-treatment cardiovascular (CV) event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack [TIA]) at any time was 7.4% lower in patients taking FF/VI 100/25mcg as compared to placebo which was not statistically noteworthy(p=0.475).
GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
WisdomTree Investments, Inc. (NASDAQ:WETF)’s shares dropped -2.90% to $17.07.
WisdomTree Investments were the target of a noteworthy growth in short interest during the month of September. As of September 15th, there was short interest totaling 15,144,142 shares, a growth of 25.6% from the August 31st total of 12,060,947 shares, Analyst Ratings Network.com reports. Based on an average daily volume of 3,024,516 shares, the days-to-cover ratio is presently 5.0 days. About 13.1% of the company’s shares are short sold.
WisdomTree Investments, Inc. is an asset management company that focuses on exchange-traded funds (ETFs). The Company’s family of ETFs includes fundamentally weighted funds that track its own indexes, funds that track third party indexes and actively managed funds. The Company distributes its ETFs through all major channels within the asset management industry, including brokerage firms, registered investment advisers, institutional investors, private wealth managers and discount brokers.
At the end of Thursday’s trade, Caesars Entertainment Corp (NASDAQ:CZR)‘s shares dipped -6.59% to $7.51.
Caesars Entertainment Corp is at a $2 billion impasse with creditors it hopes will assist keep it from sliding into bankruptcy alongside its operating unit, two people familiar with the negotiations said, according to Bloomberg.
The casino company and a committee of junior bondholders haven’t had substantive talks since last month, said the people, who requested anonymity because the negotiations are private. The bondholders are asking for about $2 billion more than Caesars has offered, according to a report by Bloomberg Intelligence analysts Philip Brendel and Julia Winters.
The bad news for Caesars doesn’t end there. It also lost the backing of another group of creditors who refused to extend a deadline for a projected deal to restructure the company’s insolvent partner. Bloomberg Reports
Caesars Entertainment Corporation (Caesars) is a holding and casino-entertainment and hospitality services company. The Company’s facilities include gaming offerings, food and beverage outlets, hotel and convention space, and non-gaming entertainment options. Its business operations include Caesars Entertainment Resort Properties; Caesars Growth Partners Casino Properties and Developments; Caesars Interactive Entertainment and Caesars Entertainment Operating Company.
Amgen, Inc. (NASDAQ:AMGN), ended its Thursday’s trading session with -1.52% loss, and closed at $143.51.
Amgen, declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted positive opinions recommending marketing authorization for:
- Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- BLINCYTO® (blinatumomab) as a conditional marketing authorization for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL).
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
